Philips sells its molecular diagnostic technology platform to Biocartis
Molecular diagnostics company Biocartis has acquired Netherlands Royal Philips Electronics’ technology platform for fully-automated DNA/RNA molecular diagnostic testing designed for applications in a wide range of patient sample testing, including oncology and infectious diseases.

Biocartis will develop, commercialize and finalize validation of the platform at its Dutch subsidiary Biocartis BV, based at the High Tech Campus in Eindhoven, the Netherlands.

Platform-related assets, including the relevant Philips patents and technology know-how, plus a number of existing Philips staff members, will be transferred to Biocartis, said Phillips.

Philips said it will focus its research program on the integration of molecular diagnostic information into clinical decision support systems to help clinicians to arrive at the correct diagnosis and choice of therapy.